The Motley Fool reports that biotech stocks surged in 2025, driven by FDA approvals and a doubling of longevity investment to $8.49 billion.

The next 10 months might be challenging for this biotech.

The biotech sector is one that's become red-hot, at least in recent years. After around a decade of stagnation, investors appear to be intent on increasing their exposure to top biotech names in the ...

With a 10.66% CAGR, Medical Biotechnology Emerges as the Cornerstone of Precision Medicine and Biopharmaceutical Innovation.Austin, United States, March 26, 2026 (GLOBE NEWSWIRE) -- Red Biotechnology ...

This biotechnology firm develops precision therapies for rare, genetically defined diseases, with a focus on targeted cancer ...

Biotechnology stocks are wrapping up 2025 on a high note, bouncing back from a rocky start to deliver some of the year’s most impressive gains. What began as a sector weighed down by tariff fears and ...

This biotech firm develops targeted oncology therapies and leverages proprietary technology to address tumor resistance ...

The words “sure-fire” and biotechnology stocks rarely go together. This is a sector of the stock market that carries higher-than-average risk. The success of these companies depends on clinical trial ...

Learning how to trade biotech stocks offers some of the most explosive profit opportunities in the entire market—but also some of its most punishing risks. Biotech stocks can double or triple ...

Biotech investors have rarely united so strongly against a Food and Drug Administration official as they did against Vinay ...